3
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Time to restart: protocol of resumption of activities of a dermatological clinic of a level II hospital in the COVID‐19 era

      article-commentary

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Two months have already passed since the World Health Organization declared COVID‐19 a global pandemic. Italy was the first European country to record an outbreak of COVID‐19, and lockdown and social distancing strategies were adopted to prevent the spread of the virus. Several countries have examined the “Italian phase‐one strategy model” for outbreak containment and adopted similar procedures: all levels of school closures, extended workplace closures, and social isolation. The Dermatological Clinic of the United Hospitals of Ancona City is a medium‐sized departmental organizational structure (SOD) belonging to the Department of Clinical and Surgical Sciences of a level II hospital with a catchment area of 800,000 inhabitants. More than 15,000 day services are recorded annually in our SOD. At the beginning of March, when the pandemic was widespread in Italy as in the rest of the world, the clinic's activities underwent a major reorganization, with a temporary suspension of all nonurgent clinical activities. The majority of the healthcare personnel, including physicians and nurses, were moved to COVID‐19 wards to deal with health emergencies. 1 Since the beginning of May in Italy, thanks to the decrease in the number of contagions (Fig. 1), the “Italian phase‐two strategy model" has been in effect, which consists of maintaining social distance and the partial resumption of productive and commercial activities. Figure 1 Absolute increase in COVID‐19 cases. The graph illustrates the new daily cases of SARS‐CoV‐2 in Italy from February 21 to May 10 2 A well‐known and generally accepted index for evaluating the pandemic trend in Italy, beyond the total contagions, is the number of patients admitted to intensive care departments. The number of hospitalizations in intensive care for COVID‐19 in Italy fell from 1,168 to 1,034, that is by 134 units, on April 14, 2020. On that same day, there was a decrease in the total number of admissions from 14,636 to 13,834, a drop of 802 units (3,000 less than 5 days earlier). 2 These instructive data led the Italian task force for outbreak containment strategies to partially resume daily routines, even in the hospital environment. This national lockdown loosening program was turned to the regional level and caused us to partially resume our activities, both inpatient and outpatient services. The protocol adopted by our clinic is described below. Following the release of nursing staff from a closed COVID‐19 unit, the inpatient ward was reopened on May 10, 2020, and it has been possible to carry out ordinary hospitalization (according to clinical priority), although access has been reduced to allocate only one patient to a hospital room. Before admission, a telephone or outpatient triage is performed to assess the symptoms of possible SARS‐CoV‐2 infection (fever >37.5 °C, and/or respiratory symptoms, and/or personal history of previous contacts with subjects infected by SARS‐CoV‐2). If the infection is suspected, the patient is automatically transferred to the emergency room for assessment; otherwise, the patient is regularly admitted, and a diagnostic swab for SARS‐CoV‐2 RNA extraction is performed. During triage operations, a comprehensive clinical evaluation, focusing not only on specific dermatological symptoms and signs of hospitalization but also on skin symptoms related to COVID‐19 (chilblains and skin rash), is generally performed. 3 , 4 Every week, the following inpatient activities are generally scheduled: three ordinary hospitalizations (variable length of hospital stay according to clinical conditions) and six daily accesses for photodynamic treatment. At present, major surgical activities are suspended, since operating rooms previously occupied by COVID‐19 patients are in the reconverting phase; reopening is scheduled for the end of May, with 2‐hour long surgical sessions twice weekly (only skin cancer surgery admitted), and shared with plastic surgeons. All patients are encouraged to wear a surgical mask when dealing with ward personnel and must perform periodic hand hygiene, regardless of their SARS‐CoV‐2 status. Similarly, all ward personnel have to wear personal protective equipment (PPE) during all diagnostic or therapeutic procedures on the patient or when dealing with colleagues. With regards to outpatient activities, since May 10, 2020, the following outpatient services have been activated: clinical consultations for general dermatology (10 medical examinations per week), pediatric dermatology (two per week), digital dermoscopy (eight per week), inflammatory and immunomediated skin diseases (five per week), surgical and nonsurgical wound dressings (20 per week), and cryotherapy/diathermy (10 per week). Outpatient services that remained active during “phase 1” of the pandemic have been empowered: oncological dermatology, dermatological follow‐up for transplanted patients, melanoma and nonmelanoma skin cancer screening visits, and outpatient surgery for melanoma and nonmelanoma skin cancer. For each outpatient service, specific clinical‐assistance pathways have been traced to protect the health of both patients and healthcare personnel. The following services are still not active: allergological dermatology, trichology, capillaroscopy, sexually transmitted infections care, and dermatology–rheumatology–gastroenterology multidisciplinary integrated activities. 1 The amount of activity has been reduced by 1/5 compared to the pre‐COVID‐19 era, which reduces the number of patients in the waiting room (20 patients in a time span of 8 hours). All programmed or deferred visits, coded as P (within 90 days) and D (within 30 days) priorities, not performed in the previous 2 months have been canceled by a regional decree, and the necessity of the visit is reassessed by the general practitioner. Only first visits and checks with urgent (U, within 72 hours) and brief (B, within 10 days) priorities are allowed in May. In any case, information technology is being improved to optimally activate telemedicine, especially for patients already under treatment, who need nonurgent assistance or therapeutic adjustments. As for outpatients, specific itineraries have been traced. The day before the visit, the patient is contacted, and a phone triage is conducted asking for information on any symptoms attributable to COVID‐19 or previous contacts with SARS‐CoV‐2 positive individuals. The patient is also reminded to come to the clinic by him/herself, only one caregiver is allowed for underage or disabled patients, and punctuality with respect to the agreed visiting time is recommended. 5 , 6 , 7 Before entering the dermatological polyclinic area, the patient's body temperature is measured and if it exceeds 37.5 °C, access is prevented. Otherwise, the patient is provided with standard single‐use PPE (surgical mask and nitrile gloves) before entering. Moreover, the patient must fill out a self‐certification form attesting current health status and any potentially at‐risk contact with SARS‐CoV‐2 positive persons. Waiting rooms of the outpatient services have been arranged to avoid crowding, guaranteeing an interpersonal distance of 2 square meters. In addition, disinfectant gels are mounted on the walls, and all spaces are sanitized three times a day. All the healthcare operators wear filtering facepiece 2 (FFP2) masks without a filter or other types of PPEs according to the procedures to be performed on the patient. In our opinion, such a complex reorganization of services is mandatory to ensure the safety of both healthcare staff and patients during the so‐called phase 2, to control virus circulation in the healthcare environment, and to prevent the hospital itself from becoming a source of an outbreak of the infection.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: found

          Global coronavirus pandemic (2019-nCOV): Implication for an Italian medium size dermatological clinic of a ii level hospital

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Skin involvement in SARS‐CoV‐2 infection: Case series

            To the Editor, Since the beginning of the well‐known severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) pandemic, skin involvement both in adults and children has been signaled. 1 , 2 However, large‐scale studies describing skin manifestations and their etiopathogenic correlation with coronavirus disease 2019 (COVID‐19) in detail have not been reported yet. Through the analysis of emerging data from literature 3 and the direct observation of three patients with COVID‐19 (SARS‐CoV‐2 detection from nasopharyngeal swab samples through RNA extraction) and dermatological manifestations, we have hypothesized different mechanisms for their development. CASE 1: A 55‐year‐old woman was admitted to the Infectious Diseases Department of the General Regional Hospital of Ancona for pyrexia, dry cough, and dyspnea. Upon admission, she had undergone nasopharyngeal swab for SARS‐CoV‐2 isolation, with positive laboratory report. The day before, she had performed a chest X‐ray showing a right parahilar pulmonary consolidation. At the admission, high‐resolution computed tomography scan of the chest revealed a diffuse bilateral ground‐glass opacity, then diagnosis of COVID‐19 interstitial pneumonia was made. Her comorbidities included obesity (BMI = 30.2) and hypertension, in treatment with Bisoprolol Fumarate 5 mg once a day. Dermatological consultation was immediately requested for skin rash appeared 72 hours before hospital admission. It was therefore observed a generalized urticarial skin rash characterized by erythematous, smooth, slightly elevated papules and wheals, associated to severe pruritus. The patient did not report neither similar episodes in the past, nor allergies to drugs or foods. Furthermore, the patient had not taken any new medication before the rash appeared. Blood test revealed normal blood count (no lymphopenia or lymphocytosis or eosinophilia), slight increase of procalcitonin serum level (0.14 ng/mL), C‐reactive protein (CRP, 12.1 mg/dL), and liver enzymes (glutamic oxaloacetic transaminase [GOT], glutamate pyruvate transaminase [GPT], lactate dehydrogenase [LDH], gamma‐glutamyl ranspeptidase [GGT] fourfold levels). A systemic treatment with intravenous daily administration of betamethasone sodium phosphate 4 mg and chlorphenamine maleate 10 mg, in addition to antiviral therapy with lopinavir/ritonavir for pneumonia, was started. In the following days urticaria improved gradually (Figure 1). Twenty‐five days after entering into hospital, the patient was discharged for resolution of pneumonia and negative extraction of SARS‐CoV‐2 RNA from her nasopharyngeal swab in two consecutive times. Figure 1 A and B, Urticarial rash in female patient on the way to recovery after bilateral interstitial pneumonia from COVID‐19. COVID‐19, coronavirus disease 2019 CASE 2: Dermatological consultation was requested from anesthesiology division because of the appearance of an urticarial rash in a 64‐year‐old patient with acute respiratory distress syndrome (PaO2/FiO2 ≤ 100 mm Hg) caused by COVID‐19 (Figure 2). Skin rash was already present at the time of hospital admission. As in previous clinical case, neither history of allergy to drugs or foods, nor recent intake of new drugs were reported into patient's medical record. Patient was, at that moment, in treatment with lopinavir/ritonavir and hydroxychloroquine from 1 week, and no new drug introduction had been made in the last 3 weeks before skin rash development. Figure 2 Urticarial rash in male patient with severe respiratory distress syndrome related to COVID‐19. COVID‐19, coronavirus disease 2019 Blood test revealed abnormal blood count with neutrophil leukocytosis (neutrophil granulocytes 8.600/mm3), and mild lymphopenia (lymphocites 700/mm3), moderate increase of pro‐calcitonin serum levels (0.87 ng/mL), marked increase of CRP (10.2 mg/dL), and liver enzymes (GOT, GPT, LDH, GGT fourfold levels) serum levels. Patient was receiving mechanical ventilation for respiratory failure. As in previous case, diagnosis of urticarial skin rash was made, and treatment with intravenous administration of methylprednisolone 40 mg/die and bilastine 20 mg/die was started. Currently, patient is still hospitalized in Anesthesiology Department, in stable clinical conditions, skin rash is slightly improved after 48 hours from the beginning of the treatment. CASE 3: A 12‐year‐old girl presented to our observation with erythematous‐oedematous purple lesions affecting the skin of the distal phalanges of all 10 toes with clear demarcation from the remaining skin of the feet (Figure 3A). Both patient and her mother reported that these chilblain‐like lesions had never occurred before, and were not accompanied by pain or itching, or other systemic symptoms. A family history of autoimmune diseases has not been reported and the patient's mother denied that her daughter suffered from other diseases or that she recently had exposure to the cold. The patient's mother reported 1 day fever occurred, 10 days before, with a single body temperature spike of 37.9°C. Patient's father had presented respiratory symptoms compatible with COVID‐19 infection about 20 days earlier, although he had not performed the diagnostic swab yet. Due to recent reports of similar skin lesions during COVID‐19, a diagnostic swab was requested, and unfortunately denied (in Italy swab is allowed only in patients with concomitant fever > 37.5°C). Figure 3 A, Chilblain‐like lesions in a SARS‐CoV‐2 positive 12 year‐old girl and (B) in 8 year‐old boy with a SARS‐CoV‐2 positive father. SARS‐CoV‐2, severe acute respiratory syndrome coronavirus‐2 Seventy‐two hours after, the patient father's nasopharyngeal swab was positive for SARS‐CoV‐2. After that, nasopharyngeal swab performed to our patient resulted positive too. Similar clinical presentations were observed few days later in another 8‐year‐old boy with father recently recovered from COVID‐19 (Figure 3B). Unfortunately, in this case nasopharyngeal swab was not performed. From the observation of these four patients, together with data from literature, it can be inferred that the attention to skin involvement during COVID‐19 should be recommended. A study carried out by Recalcati 4 on 88 patients affected by COVID‐19 showed presence of widespread urticaria (3 patients), erythematous rush (14 patients), and chickenpox‐like vesicles (1 patient). Other frequently described manifestation are chilblain‐like lesions, especially located on the feet of adolescent subjects without typical respiratory symptoms of COVID‐19, sometimes positive to the diagnostic swab. 5 There are still no studies to accurately identify which are the dermatological manifestations of COVID‐19, and why they occur. However, several hypotheses could be formulated from integration of our clinical observations and data from literature. In our opinion, skin involvement in course of SARS‐CoV‐2 may be more than a mere coincidence. Skin lesions could be ascribed into two main clinical categories: early (urticarial rash, exanthemas, and chickenpox‐like vesicles) and late (chilblains‐like lesions) cutaneous manifestations. Urticarial rash, exanthemas, chickenpox‐like vesicles occur in most cases at the beginning of respiratory symptoms (as reported in clinical cases 1 and 2), they may be related either to initial viral replication of SARS‐CoV‐2 (so‐called “viral sepsis”), or to cytokine storm characteristic of COVID‐19 disease. Not yet knowing how the above mentioned processes can occur, 6 , 7 further pathogenic hypothesis would be speculative. Other, generally later reported, COVID‐19 related skin features are chilblains‐like lesions. Many Dermatologists, around the world have reported a recent increase in chilblains‐like lesions, unrelated to cold exposure, located at the feet in adolescents. In many cases, as shown by a recent Italian study, 5 many patients have positive swab for SARS‐CoV‐2. Very few information on the histology of these skin injuries are available. One described case including skin histology in chilblain‐like lesions 8 showed an interesting superficial and deep lichenoid, perivascular and peri‐eccrine infiltrate of lymphocytes with occasional plasma cells without detection of fibrin or intra luminal thrombi. These findings, combined with evidence of their onset several days after respiratory symptoms appearance (or in the absence of symptoms) might indicate that these lesions have other origin than those of the urticarial rashes, exanthemas, and chickenpox‐like vesicles. They might be related to a secondary cell‐mediated immune response, following the initial viral infection. Further studies are needed to verify these hypotheses, however, in our opinion it is essential to focus clinical attention on all dermatological manifestations previous described, especially if they occur for the first time in healthy subjects. A careful personal and family history should be collected for each patients, even if paucisymptomatic, in this subset of patients (with a careful epidemiological investigation of possible COVID‐19 infection), claiming for SARS‐CoV‐2 nasofaryngeal swab. CONFLICT OF INTERESTS The authors declare that there are no conflict of interests.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Face the COVID‐19 emergency: measures applied in an Italian Dermatologic Clinic

              Abstract We have read with great interest the article by Radi et al. which reported the measures applied in order to limit the spread of coronavirus‐infection in their dermatological clinic. Particularly they described all the exceptional precautionary measures adopted in order to face COVID‐19‐emergency and to reduce the spread of infection. Herein we report the experience of our dermatologic Clinic (University of Naples Federico II) which has a very large catchment area and a high number of annually visits (59000 visits in the 2019).
                Bookmark

                Author and article information

                Contributors
                anna.campanati@gmail.com
                Journal
                Int J Dermatol
                Int J Dermatol
                10.1111/(ISSN)1365-4632
                IJD
                International Journal of Dermatology
                John Wiley and Sons Inc. (Hoboken )
                0011-9059
                1365-4632
                23 September 2020
                : 10.1111/ijd.15187
                Affiliations
                [ 1 ] Dermatological Clinic, Department of Clinical and Molecular Sciences Polytechnic University of the Marche Region Ancona Italy
                Author notes
                [*] [* ] Correspondence

                Anna Campanati, md

                Dermatological Clinic, Department of Clinical and Molecular Sciences

                Polytechnic Marche University

                Via Conca 71, 60020

                Ancona

                Italy

                E‐mail: anna.campanati@ 123456gmail.com

                Author information
                https://orcid.org/0000-0003-2274-1742
                https://orcid.org/0000-0003-3153-1026
                https://orcid.org/0000-0002-3740-0839
                https://orcid.org/0000-0001-7941-5089
                https://orcid.org/0000-0003-0815-172X
                https://orcid.org/0000-0002-7939-0026
                https://orcid.org/0000-0002-3033-8024
                https://orcid.org/0000-0001-5445-1200
                Article
                IJD15187
                10.1111/ijd.15187
                7537291
                32966610
                40b621e6-0f33-41e7-a69f-b8ffd1ace135
                © 2020 the International Society of Dermatology

                This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

                History
                : 29 May 2020
                : 13 July 2020
                : 26 August 2020
                Page count
                Figures: 1, Tables: 0, Pages: 3, Words: 2866
                Categories
                Commentary
                Commentary
                Custom metadata
                2.0
                corrected-proof
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.2 mode:remove_FC converted:06.10.2020

                Comments

                Comment on this article